Year-End Sale is Live! Find Exclusive Prices on the Best Selling Pharma & MedTech Reports.Check Now!

Home
report store
persistent epithelial defects epidemiology forecast

persistent-epithelial-defects-epidemiology-forecast-report

SALE

Persistent Epithelial Defects (PEDs)- Epidemiology forecast- 2034

Published Date : 2025

Pages : 100

Region : United States, Japan, EU4 & UK

SALE

Summary
TOC Table of Content
LOT
- Sample Request

persistent epithelial defects epidemiology forecast

"DelveInsight’s ‘Persistent Epithelial Disease (PED)– Epidemiology Forecast—2034’ report delivers an in-depth understanding of the Persistent Epithelial Disease, historical and forecasted epidemiology in the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom) and Japan.

Geographies Covered

• The United States

• EU5 (Germany, France, Italy, Spain, and the United Kingdom)

• Japan

Study Period: 2017–2034

Persistent Epithelial Disease (PED) Disease Understanding

The review of the literature is not able to suggest the actual incidence of PED. However, the estimated incidence based on assumptions regarding the causes of PED helped to understand possible the number of cases of PED. Overall, the estimated number of PEDs per year in the United States is roughly 73,434 −99,465 cases (Wirostko et al., 2015). The total number of incidence of PEDs is less than 200,000 in the US and is therefore considered an orphan disease in this region (Vaidyanathan et al., 2019).

Persistent Epithelial Disease, also known as persistent corneal epithelial defects (PEDs or PCEDs), results from the failure of rapid re-epithelialization and closure within 10–14 days after a corneal injury, even with standard supportive treatment. PED is defined as “defects persisting for more than 2 weeks without improvement despite conventional treatment, such as non-preservative artificial tears or extended wear soft contact lenses” (Tsubota). PEDs commonly extend into the stromal layer, causing stromal melting, secondary ulceration, and stromal scarring. Also, an insult to the cornea resulting in an acute epithelial defect is a lesion that usually heals over the 7–14 days time frame. In contrast, a persistent epithelial defect is unable to close within this normal interval.

The normal corneal wound healing process can be disrupted from defective epithelial adhesion, limbal stem cell deficiency, surface trauma, medications, infections, and several other etiologies. Such defects are especially common in individuals with metaherpes, neurotrophic keratopathy, or diabetic keratopathy.

Some of the symptoms of PEDs are loss of corneal epithelial cells, delayed epithelialization post-injury, nonhealing epithelial defect and others which can be commonly due to Epithelial/limbal, inflammatory disease, Neurotrophic, mechanical causes, and others. Evaluating a PED involves instillation of fluorescein to monitor the size, location, and depth of the defect. A thorough physical exam should reveal findings such as inflammation in the anterior chamber, eyelid abnormalities, or decreased sensation of the cornea.

Persistent Epithelial Disease (PED) Epidemiology

The Persistent Epithelial Disease epidemiology division provides insights about the historical and current patient pool along with the forecasted trend for every seven major countries. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. This part of the DelveInsight report also provides the diagnosed patient pool and their trends along with assumptions undertaken.

Key Findings

The disease epidemiology covered in the report provides historical as well as forecasted Persistent Epithelial Disease epidemiology segmented as the Total Incidence of Persistent Epithelial Disease, Etiology-specific cases. The report includes the Incident scenario of Persistent Epithelial Disease symptoms in 7MM covering the United States, EU5 countries (Germany, France, Italy, Spain, and the United Kingdom), and Japan from 2017 to 2034.

Country Wise- Persistent Epithelial Disease (PED) Epidemiology

The epidemiology segment also provides the Persistent Epithelial Disease (PED) epidemiology data and findings across the United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom) and Japan.

The total Incident population of Persistent Epithelial Disease Associated in 7MM countries estimated to be 238,058 cases in 2017.

• As per the estimates, the United States has the highest Incident population of Persistent Epithelial Disease.

• Among the EU5 countries, Germany had the highest Incident population of Persistent Epithelial Disease. On the other hand, Spain had the lowest Incident population with 15,040 in 2017.

Scope of the Report

• Persistent Epithelial Disease (PED) report covers a detailed overview explaining its causes, symptoms, classification, pathophysiology, diagnosis and treatment patterns

• Persistent Epithelial Disease (PED) Epidemiology Report and Model provide an overview of the risk factors and global trends of Persistent Epithelial Disease (PED) in the seven major markets (7MM: US, France, Germany, Italy, Spain, UK, and Japan)

• The report provides insight about the historical and forecasted patient pool of Persistent Epithelial Disease (PED) in seven major markets covering the United States, EU5 (Germany, Spain, France, Italy, UK) and Japan

• The report helps to recognize the growth opportunities in the 7MM with respect to the patient population

• The report assesses the disease risk and burden and highlights the unmet needs of Persistent Epithelial Disease

• The report provides the segmentation of the Persistent Epithelial Disease (PED) epidemiology by Incident Cases of Persistent Epithelial Disease (PED) in 7MM

• The report provides the segmentation of the Persistent Epithelial Disease (PED) epidemiology by Etiology -specific Incident Cases of Persistent Epithelial Disease (PED) in 7MM

Report Highlights

• 10-year forecast of Persistent Epithelial Disease (PED) epidemiology

• 7MM Coverage

• Total Incident Cases of Persistent Epithelial Disease (PED)

• Incident Cases according to segmentation: Etiology-specific Incidence of Persistent Epithelial Disease (PED)

KOL- Views

We interview, KOLs and SME's opinion through primary research to fill the data gaps and validate our secondary research. The opinion helps to understand the total patient population and current treatment pattern. This will support the clients in potential upcoming novel treatment by identifying the overall scenario of the indications.

Key Questions Answered

• What will be the growth opportunities in the 7MM with respect to the patient population pertaining to Persistent Epithelial Disease (PED)?

• What are the key findings pertaining to the Persistent Epithelial Disease (PED) epidemiology across 7MM and which country will have the highest number of patients during the forecast period (2017–2034)?

• What would be the total number of patients of Persistent Epithelial Disease (PED) across the 7MM during the forecast period (2017–2034)?

• Among the EU5 countries, which country will have the highest number of patients during the forecast period (2017–2034)?

• At what CAGR the patient population is expected to grow in 7MM during the forecast period (2017–2034)?

• What is the disease risk, burden and unmet needs of the Persistent Epithelial Disease?

• What are the currently available treatments of Persistent Epithelial Disease?

Reasons to buy

The Persistent Epithelial Disease (PED) Epidemiology report will allow the user to -

• Develop business strategies by understanding the trends shaping and driving the global Persistent Epithelial Disease (PED) market

• Quantify patient populations in the global Persistent Epithelial Disease (PED) market to improve product design, pricing, and launch plans

• Organize sales and marketing efforts by identifying the age groups and sex that present the best opportunities for Persistent Epithelial Disease (PED) therapeutics in each of the markets covered

• Understand the magnitude of Persistent Epithelial Disease (PED) population by its Incidence cases

• Understand the magnitude of Persistent Epithelial Disease (PED) population by its Etiology-specific cases

• The Persistent Epithelial Disease (PED) epidemiology report and model were written and developed by Masters and Ph.D. level epidemiologists

• The Persistent Epithelial Disease (PED) Epidemiology Model developed by DelveInsight is easy to navigate, interactive with dashboards, and epidemiology based on transparent and consistent methodologies. Moreover, the model supports data presented in the report and showcases disease trends over 10-year forecast period using reputable sources

Key Assessments

• Patient Segmentation

• Disease Risk and Burden

• Risk of disease by the segmentation

• Factors driving growth in a specific patient population

1. Key Insights

2. Persistent Epithelial Defect (PED): Epidemiology Overview at a Glance

2.1. Total Patient Share (%) Distribution of PED in 2017

2.2. Total Patient Share (%) Distribution of PED in 2030

3. Executive summary

4. Organizations

5. Epidemiology Methodology

6. Persistent Epithelial Disease (PED): Disease Overview

6.1. Introduction

6.2. Clinical Presentation

6.3. Etiology

6.4. Pathophysiology

6.5. Diagnosis

6.5.1. Differential diagnosis

7. Epidemiology and Patient Population

7.1.Key Findings

7.2. Total Incident cases of Persistent epithelial defect in 7MM

8. 7MM Epidemiology of Persistent Epithelial Defects

8.1. Assumptions and Rationale

8.2. United States

8.2.1. Total Incident cases of Persistent epithelial defect in the United States

8.2.2. Etiology-specific cases of Persistent epithelial defect in the United States

8.3. EU5 Countries

8.4. Germany

8.4.1. Total Incident cases of Persistent epithelial defect in Germany

8.4.2. Etiology-specific cases of Persistent epithelial defect in Germany

8.5. France

8.5.1. Total Incident cases of Persistent epithelial defect in France

8.5.2. Etiology-specific cases of Persistent epithelial defect in France

8.6. Italy

8.6.1. Total Incident cases of Persistent epithelial defect in Italy

8.6.2. Etiology-specific cases of Persistent epithelial defect in Italy

8.7. Spain

8.7.1. Total Incident cases of Persistent epithelial defect in Spain

8.7.2. Etiology-specific cases of Persistent epithelial defect in Spain

8.8. UK

8.8.1. Total Incident cases of Persistent epithelial defect in the United Kingdom

8.8.2. Etiology-specific cases of Persistent epithelial defect in the United Kingdom

8.9. Japan

8.9.1. Total Incident cases of Persistent epithelial defect in Japan

8.9.2. Etiology-specific cases of Persistent epithelial defect in Japan

9. Current Treatment Practices

10. Unmet Needs

11. SWOT Analysis

12. Case studies

12.1. Refractory case of persistent epithelial defects associated with dry eye syndrome and recurrent corneal erosions successfully treated with cyclosporine A 0.05% eye drops

12.2. Treatment of Chronic Non-healing Neurotrophic Corneal Epithelial Defects with Thymosin Beta 4

12.3. Healing Persistent Epithelial Defects: A Case Study

12.4. Rapid healing of a persistent corneal epithelial defect (PCED) with autologous serum treatment

13. KOL Views

14. Bibliography

15. Appendix

15.1. Report Methodology

16. DelveInsight Capabilities

17. Disclaimer

18. About DelveInsight

List of Tables:

List of Table

Table 1: Total Incident cases of Persistent epithelial defect in 7MM (2017–2030)

Table 2: Total Incident cases of Persistent epithelial defect in the US (2017–2030)

Table 3: Etiology-specific cases of Persistent epithelial defect in the US (2017–2030)

Table 4: Total Incident cases of Persistent epithelial defect in Germany (2017–2030)

Table 5: Etiology-specific cases of Persistent epithelial defect in Germany (2017–2030)

Table 6: Total Incident cases of Persistent epithelial defect in France (2017–2030)

Table 7: Etiology-specific cases of Persistent epithelial defect in France (2017–2030)

Table 8: Total Incident cases of Persistent epithelial defect in Italy (2017–2030)

Table 9: Etiology-specific cases of Persistent epithelial defect in Italy (2017–2030)

Table 10: Total Incident cases of Persistent epithelial defect in Spain (2017–2030)

Table 11: Etiology-specific cases of Persistent epithelial defect in Spain (2017–2030)

Table 12: Total Incident cases of Persistent epithelial defect in the UK (2017–2030)

Table 13: Etiology-specific cases of Persistent epithelial defect in the UK (2017–2030)

Table 14: Total Incident cases of Persistent epithelial defect in Japan (2017–2030)

Table 15: Etiology-specific cases of Persistent epithelial defect in Japan (2017–2030)

List of Figures:

List of Figures

Figure 1: Epidemiology and Market Methodo+C3:D19logy

Figure 2:Depiction of a Persistent Epithelial Defect (PED)

Figure 3: Clinical features

Figure 4: Clinical symptoms and their timely presentation

Figure 5: Etiologies Of Persistent Corneal Epithelial Defect

Figure 6:Normal Epithelial Wound Healing Process

Figure 7: Growth Factors and Inflammatory Mediators Involved in the Epithelial Wound Healing Process

Figure 8: Total Incident cases of Persistent epithelial defect in 7MM (2017–2030)

Figure 9: Total Incident cases of Persistent epithelial defect in the US (2017–2030)

Figure 10: Etiology-specific cases of Persistent epithelial defect in the US (2017–2030)

Figure 11: Total Incident cases of Persistent epithelial defect in Germany (2017–2030)

Figure 12: Etiology-specific cases of Persistent epithelial defect in Germany (2017–2030)

Figure 13: Total Incident cases of Persistent epithelial defect in France (2017–2030)

Figure 14: Etiology-specific cases of Persistent epithelial defect in France (2017–2030)

Figure 15: Total Incident cases of Persistent epithelial defect in Italy (2017–2030)

Figure 16: Etiology-specific cases of Persistent epithelial defect in Italy (2017–2030)

Figure 17: Total Incident cases of Persistent epithelial defect in Spain (2017–2030)

Figure 18: Etiology-specific cases of Persistent epithelial defect in Spain (2017–2030)

Figure 19: Total Incident cases of Persistent epithelial defect in the UK (2017–2030)

Figure 20: Etiology-specific cases of Persistent epithelial defect in the UK (2017–2030)

Figure 21: Total Incident cases of Persistent epithelial defect in Japan (2017–2030)

Figure 22: Etiology-specific cases of Persistent epithelial defect in Japan (2017–2030)

Table 23: Stepwise Approach for the Management of Persistent Corneal Epithelial Defects

Figure 24: Unmet Needs

Figure 25: Market Drivers

Figure 26:Market Barriers

Tags:

License Type

Offer